HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Aclarubicin

Subscribe to New Research on Aclarubicin

An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.

Also Known As:

Aclacin; Aclaplastin; Lundbeck Brand of Aclarubicin Hydrochloride; MA-144A1; Medac Brand of Aclarubicin Hydrochloride; NSC-208734; MA 144A1; MA144A1; NSC 208734; NSC208734; Aclacinomycin A; 1-Naphthacenecarboxylic acid,(2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)oxy)-, methyl ester, (1R-(1alpha,2beta,4beta))-

Networked: 306 relevant articles (29 outcomes, 68 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Jin, Jie: 6 articles (06/2015 - 01/2008)
2.	Wu, Depei: 5 articles (12/2015 - 05/2011)
3.	Liu, Limin: 4 articles (12/2015 - 01/2014)
4.	Zhang, Yanming: 4 articles (12/2015 - 01/2014)
5.	Huang, Jian: 4 articles (06/2015 - 01/2008)
6.	Tong, Yin: 4 articles (10/2013 - 01/2008)
7.	Li, Xiaoli: 3 articles (12/2015 - 03/2015)
8.	Qu, Qi: 3 articles (12/2015 - 03/2015)
9.	Lu, Hua: 3 articles (03/2015 - 10/2007)
10.	Rogalska, Aneta: 3 articles (01/2014 - 10/2008)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/01/1995 - "Aclarubicin is therefore considered a highly active drug for remission reinduction of previously treated children suffering from ANLL with an acceptable toxicity." 12/01/1987 - "Aclarubicin can produce a significant response rate in previously treated patients with acute myeloblastic leukemia and should be considered for study in initial therapy." 12/01/1987 - "Phase II study of aclarubicin in acute myeloblastic leukemia." 01/01/1987 - "In a phase I-II trial, 38 patients with acute myeloid leukemia (AML) were given single drug induction therapy with aclarubicin (ACM) according to two dosing schedules: treatment 1: 10 to 30 mg/m2/d to a maximum total dose of 300 mg/m2 or until development of unacceptable toxicity: treatment 2: 15 mg/m2/d in ten-day courses separated by ten-day intervals. " 06/01/1984 - "Phase I-II study of aclarubicin for treatment of acute myeloid leukemia."
2.	Leukemia 07/01/1992 - "The clinical efficacy of aclarubicin, an anthracycline antibiotic, was studied in 48 patients with leukemia. " 08/01/1986 - "[Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A]." 01/01/1987 - "[Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas]." 08/01/1986 - "Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study." 12/01/1980 - "A phase II study of aclacinomycin A in acute leukemia in adults."
3.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 03/01/2000 - "We have reported that low-dose aclarubicin (ACR) therapy is effective in some patients with myelodysplastic syndrome (MDS). " 12/01/1991 - "Low-dose aclarubicin has also been reported to be effective as differentiation therapy in some patients with myelodysplastic syndrome and atypical AML. " 01/01/1987 - "Treatment of four patients with myelodysplastic syndrome with a small dose of aclacinomycin-A." 01/01/1990 - "To study the therapeutic effect of low-dose aclarubicin (ACR), we carried out comparative treatment of 15 patients with myelodysplastic syndrome (MDS) and atypical leukemia using this drug. " 01/01/1990 - "Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin."
4.	Neoplasm Metastasis (Metastasis) 09/01/1997 - "ACR-CH is designed to (a) adsorb a great amount of aclarubicin and desorb in a free state; (b) distribute a greater amount of ACR for a longer period of time selectively to the regional lymph nodes; (c) be decreased in the systemic toxicity; and (d) enhance its therapeutic effect on lymph node metastases. " 12/01/1991 - "Enhanced anti-cancer effects of intralymphatic aclarubicin on distal lymph node metastases: quantitative evaluation using a new experimental model in mice." 02/01/1993 - "From these results, it appears that the new dosage form of aclacinomycin A, ACR-CH, with superior therapeutic efficacy against lymph node metastases, can also enhance the immune response of regional lymph node cells. " 11/01/2001 - "[A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT]." 09/01/1995 - "[Trial of a treatment for lymph node metastases in patients with breast cancer using aclarubicin bound to activated carbon particles]."
5.	Breast Neoplasms (Breast Cancer) 01/01/1993 - "An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs." 01/01/1993 - "We conclude that aclarubicin is inactive in metastatic breast cancer at the dose and schedule used. " 01/01/1987 - "Combination chemotherapy with aclarubicin in metastatic breast cancer." 09/01/1985 - "Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial." 01/01/1987 - "Phase II study of aclarubicin in patients with breast cancer previously untreated with adriamycin."

Related Drugs and Biologics

1.	Cytarabine (Cytosar-U)
2.	Granulocyte Colony-Stimulating Factor (G-CSF)
3.	Doxorubicin (Adriamycin)
4.	Etoposide (VP 16)
5.	CAG protocol
6.	homoharringtonine
7.	Dosage Forms (Dosage Form)
8.	Daunorubicin (Cerubidine)
9.	Cisplatin (Platino)
10.	Mitomycin (Mitomycin-C)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Remission Induction
4.	Absorbable Gelatin Sponge
5.	Salvage Therapy